Document and Entity Information
Document and Entity Information | Aug. 31, 2023 |
Cover [Abstract] | |
Amendment Flag | true |
Entity Central Index Key | 0001759425 |
Document Type | 8-K/A |
Document Period End Date | Aug. 31, 2023 |
Entity Registrant Name | Mirum Pharmaceuticals, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-38981 |
Entity Tax Identification Number | 83-1281555 |
Entity Address, Address Line One | 950 Tower Lane |
Entity Address, Address Line Two | Suite 1050 |
Entity Address, City or Town | Foster City |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94404 |
City Area Code | 650 |
Local Phone Number | 667-4085 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common stock, par value $0.0001 per share |
Trading Symbol | MIRM |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | true |
Amendment Description | On September 5, 2023, Mirum Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “Original 8-K”) reporting the Company’s completion of the acquisition of substantially all of the assets of Travere Therapeutics, Inc. (“Travere”) that are primarily related to the development, manufacture (including synthesis, formulation, finishing or packaging) and commercialization of Chenodal and Cholbam (also known as Kolbam) (such assets, the “Bile Acid Business”) pursuant to an Asset Purchase Agreement, dated July 16, 2023, by and between the Company and Travere (such transaction, the “Acquisition”). In connection with and immediately prior to the closing of the Acquisition, the Company completed a private placement of 8,000,000 shares of its common stock at a price per share of $26.25, resulting in aggregate net proceeds of approximately $202.2 million (the “PIPE”). The Company is filing this amendment to the Original 8-K (“Amendment”) to amend and supplement the Original 8-K to include historical financial statements of the Bile Acid Business and pro forma financial information as required by Items 9.01(a) and 9.01(b), respectively, of Form 8-K and that were excluded from the Original 8-K in reliance on the instructions to such items. Except as noted in this paragraph, no other information contained in the Original 8-K is amended or supplemented. This Amendment should be read together with the Original 8-K. |